Innovative Vaccine Solutions
Transforming Immunization Strategies
At Neo-Antigen Biotech, we are dedicated to pioneering vaccine development that not only protects but also empowers communities. Our commitment to innovation, scientific integrity, and collaboration drives us to create next-generation vaccines that address pressing health challenges.
Vaccine Development
Our primary focus is on the research and development of novel vaccine candidates that target a variety of infectious diseases, aiming to enhance public health and prevent outbreaks on a global scale.
Patented Technology
Utilizing our patented core technology, we are uniquely positioned to offer innovative solutions that set us apart in the competitive vaccine landscape, ensuring effective and safe immunization options.
Investor Relations
Building investor confidence is a priority for us as we showcase our groundbreaking research, compelling data, and potential for significant returns, making us an attractive opportunity for funding in the biotech sector.
Collaborative Partnerships
We actively seek collaborations with pharmaceutical companies and research institutions to leverage our expertise and expand our reach, enhancing the development and distribution of our vaccine innovations.
Our flagship project focuses on developing vaccine prototypes targeting Chagas disease and influenza. The company has secured funding for these development by grants of €2,5 million for mRNA-based pathogen vaccines demonstrating the potential and technological credibility.Neo-AG’s progress is further underscored by its growing international network and global validation efforts. Collaborations extend across multiple countries, including Brazil, the United States, and Denmark. In Brazil, the company has participated in the development of a vaccine targeting Chagas disease, while in the United States it has engaged in mRNA-related collaborations. Additionally, partnerships in Denmark focus on artificial intelligence and immune-informatics, which are essential for identifying and optimizing epitopes. These international collaborations demonstrate the scalability and scientific relevance of the platform. Technologically, the TFR123 platform aims advanced TRL4, reaching full preclinical validation. During this period, the company’s intellectual property value will grow at least twentyfold, reflecting both scientific progress and effective IP strategy.Neo-AB follows a strongly IP-driven business model, prioritizing licensing and acquisition opportunities over direct commercialization, in line with biotech industry practices. This positions the company as an attractive partner for larger pharmaceutical firms.
Looking ahead, the company seeks approximately €2 million to support further R&D and IP expansion, accelerating next-generation mRNA vaccine development and moving toward clinical stages. Overall, Neo-AG is a promising innovator in immunotherapy, with strong potential to contribute to precision immunization.